Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.92 USD | -0.76% | +7.18% | +119.21% |
May. 14 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
May. 14 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+119.21% | 739M | |
+47.02% | 57.87B | |
+40.68% | 40.25B | |
-6.52% | 39.94B | |
-5.16% | 28.54B | |
+11.11% | 26.4B | |
-20.58% | 19.33B | |
+30.53% | 12.4B | |
-1.41% | 12.23B | |
+23.14% | 12.2B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Truist Securities Adjusts Price Target on Taysha Gene Therapies to $5 From $6, Maintains Buy Rating